Sema4: A Patient-Centered Health Intelligence Company

Advancing Healthcare

through information-
driven insights
Health Intelligence Company
Centrellis™
Women's Health
Precision Oncology
Robust Research
Robust Research
Health Intelligence Company

A Health Intelligence Company That Puts Patients in the Center

Sema4 is founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease.

Learn more
Centrellis™

Centrellis

Our unique analytics platform, Centrellis, allows us to offer advanced tools to help providers better manage data for patient populations, launch new clinical studies, and easily compare patient outcomes across a healthcare system.

Learn more
Women's Health

Women’s Health

From pregnancy planning to expanded carrier screening, we deploy robust science and cutting-edge tools to give patients more actionable information all along the family journey through advanced genomic testing.

Learn more
Precision Oncology

Precision Oncology

Our family of precision oncology products and services, Sema4 Signal™, provides data-driven care solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.

Learn more
Biopharma

Biopharma

Sema4 offers an extensive portfolio of health information solutions, including pre-clinical and clinical trial support, analytics for actionable insights, and advanced sequencing services, to drive informed decision-making across the drug discovery, development, and commercialization lifecycle.

Learn more
Robust Research

Robust Research

Sema4’s internationally recognized research is run by world leaders in data science, network modeling, multiscale biotechnology, and genomics. We’ve published more than 1,000 peer-reviewed publications in the last five years and remain committed to making new biological discoveries.

Learn more
May 6th, 2021

Sema4 and CM Life Sciences Announce Filing of Preliminary Proxy Statement

Sema4 and CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, filed the preliminary proxy statement related to their proposed business combination. The filing initiates the formal SEC review process required to finalize the definitive proxy statement that will be sent to CM Life Sciences shareholders.
 Read more
April 19th, 2021

NorthShore and Sema4 Launch System-Wide Genomics Program

NorthShore University HealthSystem and Sema4 have announced the availability of a system-wide data-driven genomics program that utilizes predictive analytics to help clinicians and patients prevent, detect, and treat diseases at an early stage.
 Read more
February 10th, 2021

CNBC Covers Sema4’s Plans to Become a Publicly Traded Company

CNBC featured Sema4 on its Fast Money Halftime Report show, interviewing Sema4 Founder & CEO Eric Schadt, and Eli Casdin and Keith Meister of CM Life Sciences (NASDAQ: CMLF). CNBC covered the two companies entering into a definitive business combination agreement and how it will accelerate Sema4’s growth.
 Watch here
Featured In
Awards and Recognition
X

Back to Top
© 2021 Sema4. All rights reserved.